Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KRAS G12R

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

STK11 deletion + KRAS mutation (6)

KRAS G12C + PD-L1 overexpression (4)

KRAS mutation + PD-L1 expression (4)

CPS1 overexpression + KRAS mutation + STK11 mutation (3)

HER-2 amplification + KRAS G12D (3)

KEAP1 deletion + KRAS mutation (3)

PD-L1 overexpression + KRAS mutation (3)

EGFR exon 19 deletion + KRAS mutation (2)

KRAS G12C + PD-L1 underexpression (2)

KRAS mutation + PD-L1 negative (2)

MSI-L/dMMR + KRAS G12V (2)

AXL overexpression + KRAS G12C (1)

CDH2 overexpression + KRAS wild-type (1)

Chr t(11;14) + KRAS mutation (1)

EGFR C797S + KRAS amplification + RB1 deletion (1)

EGFR L858R + KRAS amplification + RB1 deletion (1)

EGFR T790M + KRAS amplification + RB1 deletion (1)

EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)

EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)

EGFR expression + KRAS G12C (1)

EGFR overexpression + KRAS 13D (1)

EGFR overexpression + KRAS mutation (1)

FGFR1 overexpression + KRAS G12C (1)

GNA13 deletion + KRAS mutation (1)

GOPC-ROS1 fusion + KRAS Q61H (1)

HER-2 amplification + KRAS exon 2 wild-type (1)

HER-2 amplification + KRAS wild-type (1)

HER-2 overexpression + KRAS wild-type (1)

IGF1R overexpression + KRAS mutation (1)

IR overexpression + KRAS mutation (1)

IRS2 amplification + KRAS mutation (1)

KEAP1 mutation + KRAS wild-type (1)

KRAS A146 + TMB-H (1)

KRAS G12C + PD-L1 expression (1)

KRAS G12C + PD-L1 underexpression + STK11 mutation (1)

KRAS G12D + Chr del(9)(p21) (1)

KRAS G12D + HER-2 amplification + TMB-H (1)

KRAS G12D + TP53 deletion (1)

KRAS amplification + BRAF wild-type (1)

KRAS amplification + RAS wild-type (1)

KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)

KRAS mutation + BCL2A1 overexpression (1)

KRAS mutation + CDK9 overexpression + HR positive (1)

KRAS mutation + EGFR amplification (1)

KRAS mutation + ER expression (1)

KRAS mutation + HER-2 positive (1)

KRAS mutation + HR positive (1)

KRAS mutation + PD-L1 underexpression (1)

KRAS mutation + PIK3CA wild-type (1)

KRAS mutation + PTPN11 overexpression (1)

KRAS mutation + TP53 mutation + GNA13 deletion (1)

KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)

KRAS mutation + YKL-40 overexpression (1)

KRAS wild-type + BRAF V600E (1)

KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)

KRAS mutation + STK11 mutation + AXL expression (1)

MLL-AFF1 fusion + KRAS mutation (1)

MSI-H/dMMR + KRAS G12D (1)

MSI-H/dMMR + KRAS Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

MTAP deletion + KRAS G12C (1)

PD-L1 negative + KRAS G12C (1)

PD-L1 overexpression + KRAS G12C + TP53 mutation (1)

POMK-NRG1 fusion + KRAS mutation (1)

POMK‐NRG1 fusion + KRAS G12D (1)

PTEN deletion + KRAS G12C (1)

RET positive + KRAS G12V (1)

ROS1 fusion + KRAS G12C (1)

STK11 mutation + KRAS mutation + TP53 deletion (1)

STRN-ALK fusion + KRAS G13D (1)

TP53 S12F + KRAS G12D + TMB-L (1)

HER-2 amplification + KRAS G12C (0)

PRMT5 overexpression + KRAS mutation (0)

STK11 deletion + KRAS mutation (6)

KRAS G12C + PD-L1 overexpression (4)

KRAS mutation + PD-L1 expression (4)

CPS1 overexpression + KRAS mutation + STK11 mutation (3)

HER-2 amplification + KRAS G12D (3)

KEAP1 deletion + KRAS mutation (3)

PD-L1 overexpression + KRAS mutation (3)

EGFR exon 19 deletion + KRAS mutation (2)

KRAS G12C + PD-L1 underexpression (2)

KRAS mutation + PD-L1 negative (2)

MSI-L/dMMR + KRAS G12V (2)

AXL overexpression + KRAS G12C (1)

CDH2 overexpression + KRAS wild-type (1)

Chr t(11;14) + KRAS mutation (1)

EGFR C797S + KRAS amplification + RB1 deletion (1)

EGFR L858R + KRAS amplification + RB1 deletion (1)

EGFR T790M + KRAS amplification + RB1 deletion (1)

EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)

EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)

EGFR expression + KRAS G12C (1)

EGFR overexpression + KRAS 13D (1)

EGFR overexpression + KRAS mutation (1)

FGFR1 overexpression + KRAS G12C (1)

GNA13 deletion + KRAS mutation (1)

GOPC-ROS1 fusion + KRAS Q61H (1)

HER-2 amplification + KRAS exon 2 wild-type (1)

HER-2 amplification + KRAS wild-type (1)

HER-2 overexpression + KRAS wild-type (1)

IGF1R overexpression + KRAS mutation (1)

IR overexpression + KRAS mutation (1)

IRS2 amplification + KRAS mutation (1)

KEAP1 mutation + KRAS wild-type (1)

KRAS A146 + TMB-H (1)

KRAS G12C + PD-L1 expression (1)

KRAS G12C + PD-L1 underexpression + STK11 mutation (1)

KRAS G12D + Chr del(9)(p21) (1)

KRAS G12D + HER-2 amplification + TMB-H (1)

KRAS G12D + TP53 deletion (1)

KRAS amplification + BRAF wild-type (1)

KRAS amplification + RAS wild-type (1)

KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)

KRAS mutation + BCL2A1 overexpression (1)

KRAS mutation + CDK9 overexpression + HR positive (1)

KRAS mutation + EGFR amplification (1)

KRAS mutation + ER expression (1)

KRAS mutation + HER-2 positive (1)

KRAS mutation + HR positive (1)

KRAS mutation + PD-L1 underexpression (1)

KRAS mutation + PIK3CA wild-type (1)

KRAS mutation + PTPN11 overexpression (1)

KRAS mutation + TP53 mutation + GNA13 deletion (1)

KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)

KRAS mutation + YKL-40 overexpression (1)

KRAS wild-type + BRAF V600E (1)

KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)

KRAS mutation + STK11 mutation + AXL expression (1)

MLL-AFF1 fusion + KRAS mutation (1)

MSI-H/dMMR + KRAS G12D (1)

MSI-H/dMMR + KRAS Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

MTAP deletion + KRAS G12C (1)

PD-L1 negative + KRAS G12C (1)

PD-L1 overexpression + KRAS G12C + TP53 mutation (1)

POMK-NRG1 fusion + KRAS mutation (1)

POMK‐NRG1 fusion + KRAS G12D (1)

PTEN deletion + KRAS G12C (1)

RET positive + KRAS G12V (1)

ROS1 fusion + KRAS G12C (1)

STK11 mutation + KRAS mutation + TP53 deletion (1)

STRN-ALK fusion + KRAS G13D (1)

TP53 S12F + KRAS G12D + TMB-L (1)

HER-2 amplification + KRAS G12C (0)

PRMT5 overexpression + KRAS mutation (0)

›

Related tests:

therascreen® KRAS RGQ PCR Kit (5)

therascreen® KRAS RGQ PCR Kit (5)

DC Vaccine in Pancreatic Cancer (NCT03592888)

Phase 1

University of Pennsylvania

University of Pennsylvania

Completed

Phase 1

University of Pennsylvania

Completed

Last update posted :

05/07/2024

Initiation :

11/20/2018

Primary completion :

02/12/2024

Completion :

02/12/2024

KRAS • HLA-A

|

KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy (NCT05630989)

Phase N/A

Mandana Kamgar, MD

Mandana Kamgar, MD

Recruiting

Phase N/A

Mandana Kamgar, MD

Recruiting

Last update posted :

04/11/2024

Initiation :

02/07/2023

Primary completion :

02/01/2025

Completion :

02/01/2025

KRAS

|

KRAS mutation • KRAS G12R • KRAS G12

|

hydroxychloroquine

KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC (NCT05254184)

Phase 1

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sidney Kimmel Comprehensive Cancer Cent...

Recruiting

Phase 1

Sidney Kimmel Comprehensive Cancer Center at Jo...

Recruiting

Last update posted :

01/24/2024

Initiation :

11/01/2022

Primary completion :

04/01/2025

Completion :

04/01/2027

KRAS

|

KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12R • KRAS G12A • KRAS G12 • KRAS G13

|

Opdivo (nivolumab) • Yervoy (ipilimumab)

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations (NCT03040986)

Phase 2

National Cancer Institute (NCI)

National Cancer Institute (NCI)

Completed

Phase 2

National Cancer Institute (NCI)

Completed

Last update posted :

02/09/2021

Initiation :

07/21/2017

Primary completion :

08/10/2018

Completion :

10/15/2020

KRAS • RAS

|

KRAS mutation • KRAS wild-type • KRAS G12R • RAS wild-type • KRAS G12

|

Koselugo (selumetinib)